CACCIARI, Barbara
 Distribuzione geografica
Continente #
NA - Nord America 11.259
AS - Asia 5.930
EU - Europa 4.682
SA - Sud America 1.027
AF - Africa 92
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 22.998
Nazione #
US - Stati Uniti d'America 11.053
FI - Finlandia 2.064
SG - Singapore 2.020
CN - Cina 1.673
BR - Brasile 798
UA - Ucraina 695
VN - Vietnam 664
DE - Germania 517
HK - Hong Kong 494
TR - Turchia 482
GB - Regno Unito 365
SE - Svezia 235
FR - Francia 211
IT - Italia 203
RU - Federazione Russa 157
IN - India 122
JP - Giappone 119
MX - Messico 104
AR - Argentina 85
CA - Canada 81
BD - Bangladesh 69
PL - Polonia 67
EC - Ecuador 44
ID - Indonesia 43
ZA - Sudafrica 42
IQ - Iraq 41
PK - Pakistan 33
NL - Olanda 32
CO - Colombia 27
BE - Belgio 23
ES - Italia 23
VE - Venezuela 21
SA - Arabia Saudita 20
PY - Paraguay 18
PH - Filippine 17
MY - Malesia 16
UZ - Uzbekistan 16
LT - Lituania 13
MA - Marocco 13
TW - Taiwan 13
AE - Emirati Arabi Uniti 12
IE - Irlanda 12
AT - Austria 11
CL - Cile 11
PE - Perù 11
TN - Tunisia 10
KZ - Kazakistan 8
AL - Albania 7
JO - Giordania 7
NP - Nepal 7
AZ - Azerbaigian 6
LB - Libano 6
UY - Uruguay 6
BO - Bolivia 5
CZ - Repubblica Ceca 5
EG - Egitto 5
IR - Iran 5
KE - Kenya 5
KG - Kirghizistan 5
KR - Corea 5
PA - Panama 5
RO - Romania 5
AU - Australia 4
BG - Bulgaria 4
BY - Bielorussia 4
CH - Svizzera 4
CR - Costa Rica 4
ET - Etiopia 4
RS - Serbia 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
DK - Danimarca 3
KW - Kuwait 3
MN - Mongolia 3
PS - Palestinian Territory 3
PT - Portogallo 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CI - Costa d'Avorio 2
HN - Honduras 2
HU - Ungheria 2
IL - Israele 2
LV - Lettonia 2
LY - Libia 2
MD - Moldavia 2
ME - Montenegro 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
OM - Oman 2
AF - Afghanistan, Repubblica islamica di 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
GP - Guadalupe 1
GR - Grecia 1
Totale 22.984
Città #
Helsinki 1.915
Singapore 1.262
Ashburn 1.173
Woodbridge 977
Fairfield 914
Dallas 856
Houston 779
Jacksonville 712
Chandler 593
San Jose 530
Ann Arbor 488
Hong Kong 483
Santa Clara 440
Beijing 399
Seattle 366
Wilmington 358
Cambridge 264
Nanjing 243
Izmir 222
Ho Chi Minh City 213
Princeton 158
Hanoi 153
Los Angeles 133
Lauterbourg 117
Tokyo 114
Boardman 112
San Diego 91
Shenyang 77
São Paulo 77
New York 68
Nanchang 67
Mexico City 64
Munich 62
Dong Ket 61
Hefei 60
Warsaw 58
Orem 50
Shanghai 47
Ferrara 44
Milan 44
Jiaxing 41
Tianjin 41
San Mateo 37
Brooklyn 36
London 36
Council Bluffs 34
Falkenstein 34
Hebei 34
Chicago 32
Kunming 32
Changsha 31
Jinan 31
Zhengzhou 31
Chennai 30
Dearborn 30
Rio de Janeiro 29
Da Nang 27
Frankfurt am Main 27
Falls Church 26
San Francisco 26
Buffalo 23
Philadelphia 23
Amsterdam 22
Brussels 22
Montreal 22
Norwalk 22
Moscow 21
Haiphong 20
Manchester 20
Phoenix 20
Stockholm 20
Baghdad 19
Jakarta 19
Johannesburg 19
Ningbo 19
Turku 19
Denver 18
Guangzhou 18
Toronto 18
Addison 17
Istanbul 16
The Dalles 16
Biên Hòa 15
Hải Dương 15
Bremen 14
Mountain View 14
Taizhou 14
Tashkent 14
Atlanta 13
Curitiba 13
Quito 13
Verona 13
Boston 12
Dublin 12
Guayaquil 12
Montréal 12
Mumbai 12
Porto Alegre 12
Redwood City 12
Salvador 12
Totale 16.156
Nome #
1,2,3-triazolo[5,4-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: A new class of A(2A) adenosine receptor antagonists 3.035
[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid inhibits DNA binding to transcription factor Sp1 523
1-methyl-3-nitro-5-methoxycarbonyl pyrazole 287
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 258
6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors 244
[H-3]MRE 3008F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors 228
1H-pyrazolo[2,3-d][1,2,4]triazine-3,7-diones as a new class of human leukocyte elastase inhibitors 222
5-heteroarylcarbamoylamino-pyrazolo-triazolo pyrimidines as hA3 adenosine receptor antagonists. 217
Synthesis, in vitro antiproliferative activity, and DNA-binding properties of hybrid molecules containing pyrrolo[2,1-c][1,4] benzodiazepine and minor-groove-binding oligopyrrole carriers 214
7-substituted-5-amino-2-(furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: importance of modifications at the side chain on the activity and solubility. 209
Schematic overview of oligosaccharides, with survey on their major physiological effects and a focus on milk ones 208
A new synthetic approach to indazole synthesis 206
7-substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A(2A) adenosine receptor antagonists: A study on the importance of modifications at the side chain on the activity and solubility 206
Antiproliferative effects of novel synthetic nucleobase analogues on U937 Histiocytic lymphoma cell line 203
Design, synthesis, in vitro antiproliferative activity and apoptosis-inducing studies of 1-(3',4',5'-trimethoxyphenyl)-3-(2'-alkoxycarbonylindolyl)-2-propen-1-one derivatives obtained by a molecular hybridisation approach 201
8-(2-Furyl)adenine derivatives as A₂A adenosine receptor ligands 200
1H-pyrazolo[4,3-d]pyrimidine-7(6H)-one and 5H-pyrazolo[4,3-d] 1,2,3-triazin-4(3H)-one derivatives. Synthesis and in vitro biological activity at adenosine A1 and A2a receptors 200
[3H]-MRE 3008-F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. 195
7-sobstituted-5-amino-2-(furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonist: importance of modifications at the side chain on the activity and solubility. 191
[3H]MRE3008-F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. 187
New potent and selective human adenosine A3 receptor antagonists. 184
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 183
The influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl moiety on the adenosine receptors affinity profile of pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c] pyrimidine derivatives 180
Solid lipid microparticles for the stability enhancement of a dopamine prodrug 179
Synthesis and properties of substituted CBI analogs of CC-1065 and the duocarmycins incorporating the 7-methoxy-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (MCBI) alkylation subunit: Magnitude of electronic effects on the functional reactivity 175
New potent and selective human adenosine A3 receptor antagonists 174
Resolution of a CPzI precursor, synthesis and biological evaluation of (+) and (-)-N-Boc-CPzI: A further validation of the relationship between chemical solvolytic stability and cytotoxicity 173
Synthesis and antitumor activity of novel distamycin derivatives 171
Oligonucleotides and oligonucleotide conjugates: A new approach for cancer treatment 171
Synthesis and calcium antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(nitrogenous heteroaryl)-3,5-pyridine dicarboxylates. 169
A(1) and A(3) adenosine receptor agonists: an overview 168
DNA minor groove alkylating agents structurally related to distamycin A 166
Synthesis and antitumor activity of a new class of pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone analogs of pyrrolo[1,4]benzodiazepines (PBDs) 165
Carbon nanotube substrates boost neuronal electrical signaling 163
A novel class of pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A3 adenosine receptor antagonists 163
Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors 162
Nitrile oxide [3 + 2] cycloaddition: application to the synthesis of 6-substituted 3(2H)-pyridazinones and 6-substituted 4,5-dihydro-4-hydroxy-3(2H)-pyridazinones 161
Recent developments in the field of adenosine receptor ligands 159
Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors 159
A Novel Conjugated Agent between Dopamine and an A(2A) Adenosine Receptor Antagonist as a Potential Anti-Parkinson Multitarget Approach. 157
A2A-adenosine receptor reserve for coronary vasodilation 156
DNA minor-groove binders: results and design of new antitumor agents 155
Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo- pyrimidine antagonists binding site of the human adenosine A2A receptor 155
Synthesis and Antitumor Activity of a New Class of Pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone Analogs of Pyrrolo[1,4][2,1-c]benzodiazepines 155
Synthesis and Biological Evaluation of a New Series of 1,2,4-Triazolo[1,5-a]-1,3,5-triazines as Human A(2A) Adenosine Receptor Antagonists with Improved Water Solubility 155
An efficient procedure for the synthesis of 5H-6-substituted-pyrazolo[1,5-d]-1,2,4-triazine-4,7-diones 154
Chemical Synthesis of [13C]Daidzein 154
A(3) adenosine receptor ligands: History and perspectives 152
Ethyl (R,S)-5-acetyl-4,5-dihydro-3-isoxazoleacetate 152
Synthesis and biological evaluation of new antitubulin agents containing 2-(30,40,50-trimethoxyanilino)-3,6-disubstituted-4,5,6,7-tetrahydrothieno[2,3-c]pyridine Scaffold 152
Structure-activity relationship of novel tallimustine derivatives: Synthesis and antitumor activity 151
Cosmetic preservation and structure-activity relationships of 4-diazo-pyrazole-5-carboxamides 151
New 9-methyl-8-(4-hydroxyphenyl)adenine derivatives as A1 adenosine receptor antagonists 151
Ethyl-(R,S)-5-acetyl-4,5-dihydro-3-isoxazole acetate 150
Design, synthesis and biological activity of a pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid 150
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile 150
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes 149
Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c] [1,4]benzodiazepines 147
Unusual Ring-Opening Reaction of 6,7-Dihydrothieno[3,2-d]pyrimidine- 2,4-dione Derivatives Leading to 5-(Alkylthio)-6-vinyluracils 146
Selective binding to human genomic sequences of two synthetic analogues structurally related to U-71184 and adozelesin 145
Synthesis and Biological Evaluation of Highly Active 7-Anilino Triazolopyrimidines as Potent Antimicrotubule Agents 145
Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as potential adenosine receptor antagonists 144
Facile and versatile route to the synthesis of fused 2-pyridones: Useful intermediates for polycyclic sytems 143
The Significance of 2-Furyl Ring Substitution with a 2-(para-substituted) Aryl Group in a New Series of Pyrazolo-triazolo-pyrimidines as Potent and Highly Selective hA3 Adenosine Receptors Antagonists: New Insights into Structure-Affinity Relationship and Receptor-Antagonist Recognition 143
Synthesis and preliminary biological evaluation of [H-3]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A(3) adenosine receptors 142
Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists 141
Synthesis of pyridazine derivatives through the unexpected intermediate 5-amino-4-cyano-2,3-dihydro-furan-2,3-disulfonic acid disodium salt 140
Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: Irreversible antagonists at the human A(3) adenosine receptor and molecular modeling studies 139
CC-1065 and the duocarmycins: recent developments 138
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: Potent and selective A2A adenosine antagonists 138
Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling 138
Carbon Nanotubes Carrying Cell-Adhesion Peptides do not Interfere with Neuronal Functionality 136
Exploring Potency and Selectivity Receptor Antagonist Profiles Using a Multilabel Classification Approach: The Human Adenosine Receptors as a Key Study 135
Pyridazine nucleus: a pharmacophoric moiety for bio-active compounds 133
Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors 133
Pyrazolo [4,3-E]1,2,4-triazolo[1,5-c]pyrimidine derivates a new class of potent and selective human A3 adenosine receptor antagonists. 132
Synthesis and cardiodepressant activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(pentatomic-heteroaryl)-3,5-pyridinedicarboxylates. 2 128
Comparative molecular field analysis (CoMFA) of a series of selective adenosine receptor A(2A) antagonists 127
Conjugation of Dopamine and an A2A Adenosine Receptor Antagonist: a possible approach for the treatment of Parkinson’s Disease. 126
Synthesis and molecular investigation of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivates as human A3 adenosine receptor antagonists. 125
Substituted 6-amino-thiouracils as new P2Y(12) receptor antagonists 123
Novel N-6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A(3) adenosine receptors 123
Synthesis and Biological Activity of a New Series of N6-Arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-Carboxamido Derivatives of Adenosine-5'-N-ethyluronamide as A1 and A3 Adenosine Receptor Agonists 123
Synthesis of the tritium labeled SCH 58261, a new non-xanthine A(2A) adenosine receptor antagonist 121
Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process 121
Synthesis, biological and modeling studies of new water soluble hA3 adenosine receptor antagonists. 119
Heterocyclic analogs of DNA minor groove alkylating agents 118
Current developments of A(2a) adenosine receptor antagonists 118
null 118
Synthesis and molecular investigation of new pyrazolo[4,3-e]1,2,4,-triazolo[1,5-c]pyrimidine derivates as human A3 adenosine receptor antagonists. 118
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]-pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists 117
Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist 117
A2Aadenosine receptor antagonists as therapeutic candidates: Are they still an interesting challenge? 116
Synthesis, antibacterial activity and structure-activity relationships of N-substituted 4-diazopyrazole-5-carboxamides. 2 115
Rationale design of new human adenosione A3 receptor antagonists through a CoMFA model. 115
Synthesis, binding and thermodynamic studies of new highly selective A2A adenosine receptor antagonists 115
Synthesis and pharmacological characterization of [3H]-MRE3008F20: the first radioligand antagonist for the human A3 adenosine receptors. 114
Binding affinity of adenosine receptor agonists and antagonists at human A3 adenosine receptors 114
Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: A new pharmacological tool for the characterization of the human A(3) adenosine receptor 114
Synthesis, antiviral and antiproliferative activity of a new class of 5-(alkyl or arylthio)-6-vinyl uracils 114
Totale 18.925
Categoria #
all - tutte 91.799
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 501
Totale 92.300


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021573 0 0 0 0 0 0 0 0 0 188 232 153
2021/20221.361 39 138 78 135 85 51 42 83 38 98 153 421
2022/20231.317 158 63 26 171 220 223 31 118 173 8 73 53
2023/2024810 70 92 34 21 71 60 20 260 12 12 10 148
2024/20252.595 75 134 196 79 329 171 55 201 395 316 379 265
2025/20269.318 660 559 1.299 1.011 901 422 749 334 2.539 844 0 0
Totale 23.119